Correlation Between Karyopharm Therapeutics and Catalyst Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Catalyst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Catalyst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Catalyst Pharmaceuticals, you can compare the effects of market volatilities on Karyopharm Therapeutics and Catalyst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Catalyst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Catalyst Pharmaceuticals.

Diversification Opportunities for Karyopharm Therapeutics and Catalyst Pharmaceuticals

0.26

Correlation Coefficient

Karyopharm Therapeutics  Catalyst Pharmaceuticals

Modest diversification

The 3 months correlation between Karyopharm and Catalyst is 0.26. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Catalyst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Catalyst Pharmaceuticals and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Catalyst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Catalyst Pharmaceuticals has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Catalyst Pharmaceuticals go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Catalyst Pharmaceuticals

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Catalyst Pharmaceuticals. In addition to that, Karyopharm Therapeutics is 1.99 times more volatile than Catalyst Pharmaceuticals. It trades about -0.06 of its total potential returns per unit of risk. Catalyst Pharmaceuticals is currently generating about 0.14 per unit of volatility. If you would invest  1,504  in Catalyst Pharmaceuticals on September 25, 2024 and sell it today you would earn a total of  659.00  from holding Catalyst Pharmaceuticals or generate 43.82% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Catalyst Pharmaceuticals

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Karyopharm Therapeutics is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders.

Catalyst Pharmaceuticals

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Catalyst Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Catalyst Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Karyopharm Therapeutics and Catalyst Pharmaceuticals

The main advantage of trading using opposite Karyopharm Therapeutics and Catalyst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Catalyst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will offset losses from the drop in Catalyst Pharmaceuticals' long position.

The idea behind Karyopharm Therapeutics and Catalyst Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.